Physician

Daniel S. Sa, MD

According to 2025 Medicare claims, Daniel Sa, MD (NPI: 1427075308) practices neurology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is US NEUROSCIENCE INSTITUTE PLLC (NPI: 1578218244; TIN: 874545901) and primary practice location at 78501-2356. Sa is affiliated with the CHRISTUS Health Quality Care Alliance (ACO ID: A3029), participating under the MSSP model.

Sa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 222 traditional Medicare patients, billed 777 HCPCS/CPT codes, and received $143,000 in Medicare payments. The top billing code was 95816 (Measurement of brain wave activity (eeg), awake and drowsy). Part D data shows 1,516 prescription claims across 630 beneficiaries totaling $292,896 in drug costs, led by Nuplazid (Pimavanserin Tartrate). 2019 DME data shows 20 claims. Open Payments data shows 48 records totaling $1,601. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $322,986 to $143,000. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $165,210 and ending at $292,896. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,136 to $619.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	507	11,326	$322,986
2016	626	11,164	$439,900
2017	603	9,754	$370,969
2018	508	5,811	$215,282
2019	364	4,556	$126,242
2020	33	57	$4,053
2021	60	118	$10,512
2022	85	154	$13,114
2023	99	167	$13,880
2024	222	777	$143,000

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	369	1,645	$165,210
2016	400	2,608	$177,897
2017	498	3,406	$300,524
2018	463	2,771	$246,277
2019	394	2,056	$189,972
2020	418	1,010	$121,969
2021	550	1,877	$167,232
2022	628	2,157	$214,691
2023	764	2,736	$281,790
2024	630	1,516	$292,896

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	37	$1,094
2018	N/R	21	$610
2019	N/R	20	$844
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
95816	Measurement of brain wave activity (eeg), awake and drowsy	78	79	$291
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	61	61	$163
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	69	69	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	73	86	$83
93040	Electrocardiogram (ecg) 1 to 3 leads with review by physician	49	49	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nuplazid	Pimavanserin Tartrate	11	400	$75,124
Botox	Onabotulinumtoxina	12	1,074	$13,621
Memantine Hcl	Memantine Hcl	234	18,809	$9,021
Carbidopa-Levodopa	Carbidopa/Levodopa	267	22,426	$7,105
Rivastigmine	Rivastigmine Tartrate	42	2,530	$2,672

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	48	$1,601	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel S. Sa, MD?

Tedicare shows public-source Medicare data for Daniel S. Sa, MD (NPI 1427075308), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel S. Sa, MD have ACO affiliation data?

Daniel S. Sa, MD is shown with ACO affiliation data for CHRISTUS Health Quality Care Alliance (MSSP, ACO ID A3029).

What billing organization is linked to Daniel S. Sa, MD?

Daniel S. Sa, MD is linked to US NEUROSCIENCE INSTITUTE PLLC (billing NPI 1578218244) in the available physician profile data.

Does Daniel S. Sa, MD have Open Payments data?

Daniel S. Sa, MD has 48 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.